EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Thirty-day outcomes from the Disrupt PAD BTK II study of the Shockwave Intravascular Lithotripsy System for treatment of calcified below-the-knee peripheral arterial disease

Venita Chandra, Alexandra J Lansky, Sameh Sayfo, Nicolas W Shammas, Peter Soukas, James Park, Michael Siah, Anvar Babaev, Ryan Shields, Nick E J West, Ehrin Armstrong

Journal of Vascular Surgery · 2025-03 · 81 (3) · 710-719.e2

DOI: 10.1016/j.jvs.2024.11.003 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Vascular Surgery, 2025-03. Verfasst von Venita Chandra und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Stanford University Medical Center, Palo Alto, CA. Electronic address: vchandra@stanford.edu. Hauptthemen laut MEDLINE: Peripheral Arterial Disease, Lithotripsy, Vascular Calcification, Endovascular Procedures. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Below-the-knee (BTK) lesions may be particularly challenging to treat owing to length, diffuse disease, and extent of calcification. Landmark interventional clinical studies have not reached consensus on the optimal standard of care for BTK lesions, and many published trials excluded patients with moderate or severe lesion calcification. Calcium modification with intravascular lithotripsy (IVL) was shown to be superior to percutaneous transluminal angioplasty in the femoropopliteal artery and successful in treating BTK lesions in pilot studies. The Disrupt BTK II study is a core laboratory-adjudicated, prospective, multicenter, single-arm study of patients with moderate to severely calcified BTK lesions treated with the Shockwave Medical Peripheral IVL System. METHODS: Disrupt BTK II enrolled 250 subjects with calcified infrapopliteal lesions and Rutherford category 3-5 presentation from 38 sites in the United States and Europe. The primary safety endpoint was major adverse limb events or postoperative death at 30 days, a composite of all-cause death, above-ankle amputation of the index limb, and/or major reintervention of the index limb involving an infrapopliteal artery. The primary effectiveness endpoint was procedural success, defined as ≤50% residual stenosis for all treated target lesions without serious core laboratory-adjudicated serious angiographic complications. The study used independent angiographic and duplex ultrasound core laboratories, and follow-up is planned through 2 years. RESULTS: A total of 305 lesions in 250 patients were treated with a procedural success of 97.9%. The mean target lesion length was 76 ± 65 mm, diameter stenosis was 78% ± 18%, and 84.8% had moderate or severe calcification as assessed by an independent angiographic core laboratory. After IVL, residual stenosis was reduced to 29%, and after optional postdilatation and/or stent implantation, to 26%. At 30 days, there were no deaths, major adverse limb event rate was 0.8%, and mean improvement in Vascular Quality of Life scores was 4.0 ± 5.0 (P < .0001). Of the patients with baseline wounds, 15.8% healed and 53.4% were improved at 30 days. CONCLUSIONS: The Disrupt PAD BTK II study demonstrated that treatment with the Shockwave Medical Peripheral IVL System in patients with moderate-severe calcified lesions resulted in high procedural success, significant reduction in residual stenosis, improvements in patient quality of life, and wound healing, with minimal adverse events at 30-day follow-up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peripheral Arterial DiseaseLithotripsyVascular CalcificationEndovascular ProceduresHumansMaleFemaleTreatment OutcomeAgedProspective StudiesTime FactorsMiddle AgedUnited StatesEuropeLimb SalvageAmputation, SurgicalSeverity of Illness IndexAged, 80 and overRisk FactorsVascular PatencyPopliteal Artery

Stichwörter der Autor:innen

Calcium modificationInfrapopliteal atherosclerosisIntravascular lithotripsyPeripheral arterial disease

Autor:innen und Institutionen

  • Department of Surgery, Stanford University Medical Center, Palo Alto, CA. Electronic address: vchandra@stanford.edu.
  • Department of Cardiology, Yale Cardiovascular Research Group, New Haven, CT.
  • Department of Interventional Cardiology, Baylor Scott and White, The Heart Hospital Plano, Plano, TX.
  • Division of Cardiology, Midwest Cardiovascular Research Foundation, Davenport, IA.
  • Department of Interventional Cardiology, The Miriam Hospital-Cardiology Incorporated, Providence, RI.
  • Department of Surgery, Texas Health Presbyterian Hospital, Dallas, TX.

Zitieren

APA

Chandra, V., Lansky, A. J., Sayfo, S., Shammas, N. W., Soukas, P., Park, J., Siah, M., Babaev, A., Shields, R., West, N. E. J., & Armstrong, E. (2025). Thirty-day outcomes from the Disrupt PAD BTK II study of the Shockwave Intravascular Lithotripsy System for treatment of calcified below-the-knee peripheral arterial disease. Journal of Vascular Surgery, 81(3), 710-719.e2. https://doi.org/10.1016/j.jvs.2024.11.003

Vancouver

Chandra V, Lansky AJ, Sayfo S, Shammas NW, Soukas P, Park J, et al. Thirty-day outcomes from the Disrupt PAD BTK II study of the Shockwave Intravascular Lithotripsy System for treatment of calcified below-the-knee peripheral arterial disease. Journal of Vascular Surgery. 2025;81(3):710-719.e2. doi:10.1016/j.jvs.2024.11.003

BibTeX
@article{Chandra2025,
  author = {Chandra, Venita and Lansky, Alexandra J and Sayfo, Sameh and Shammas, Nicolas W and Soukas, Peter and Park, James and Siah, Michael and Babaev, Anvar and Shields, Ryan and West, Nick E J and Armstrong, Ehrin},
  title = {Thirty-day outcomes from the Disrupt PAD BTK II study of the Shockwave Intravascular Lithotripsy System for treatment of calcified below-the-knee peripheral arterial disease},
  journal = {Journal of Vascular Surgery},
  year = {2025},
  volume = {81},
  number = {3},
  pages = {710--719.e2},
  doi = {10.1016/j.jvs.2024.11.003}
}
Kostenlos starten →